Moderna (MRNA)
(Delayed Data from NSDQ)
$163.33 USD
+19.64 (13.67%)
Updated May 22, 2024 04:00 PM ET
After-Market: $163.16 -0.17 (-0.10%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Moderna, Inc. [MRNA]
Reports for Purchase
Showing records 181 - 200 ( 254 total )
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Pulling Back the Curtains on Phase 3 in COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Dial In On Jun. 16 For Real-Life Insights into MMA from the Patient Perspective
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Taking COVID19 Vaccine by the Horns with Strong Interim Ph1 Data
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 - COVID-19 Response Paves the Way for Full Prophylactic Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Vol. 42: How to Keep an Eye in the Sky to Spot COVID-19 Infections
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Vol. 38: MRNA Vaults to the Head of the Pack for COVID Testing
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Vol. 30: BARDA Award Provides Lift-off for Moderna''s COVID Vaccine
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Vol. 29: Four Wins on the COVID-19 Front
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y